Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Salvador Martin Algarra"'
Autor:
V. E. Castellon, L. de la Cruz, Ivan Marquez-Rodas, Enrique Espinosa, Ana Arance, Maria Gonzalez Cao, Ainara Soria, J. L. G. Larriba, Salvador Martin Algarra, Alfonso Berrocal
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical & Translational Oncology
CLINICAL & TRANSLATIONAL ONCOLOGY
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
Consejería de Sanidad de la Comunidad de Madrid
Clinical & Translational Oncology
CLINICAL & TRANSLATIONAL ONCOLOGY
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f928b5c42b98a645238e5674e3ec85
https://hdl.handle.net/10171/65645
https://hdl.handle.net/10171/65645
Autor:
Ainara Soria, Alfonso Berrocal, Maria Gonzalez Cao, I. Márquez, Salvador Martin Algarra, A. G. Castano, J. L. G. Larriba, Ana Arance, Enrique Espinosa, José Antonio López Martín
Publikováno v:
Clinical & Translational Oncology
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with
Autor:
Ivan Marquez-Rodas, Salvador Martin Algarra, Sara Custodio Cabello, Miguel Martín, José Antonio Avilés Izquierdo
Publikováno v:
Clinical and Translational Oncology. 13:787-792
Melanoma is the deadliest cutaneous malignancy and its incidence continues to grow. Until 2011, the treatment options for metastatic melanoma were scarce and without any overall survival benefi t. The emergence of new targeted therapies for BRAF muta
Autor:
Karmele Mujika, Pablo Luna, Victoria Eugenia Castellón Rubio, Javier Pérez Altozano, María José Lecumberri Biurrun, Jose Luis Manzano, María Eugenia Ortega, Virtudes Soriano, José Antonio López Martín, Delvys Rodriguez-Abreu, Luis Antonio Fernandez-Morales, Salvador Martin Algarra, Jordi Rubió-Casadevall, Anabel Ballesteros, Almudena Garcia, Ivan Marquez-Rodas, Teresa Puértolas Hernández, María Rodríguez de la Borbolla Artacho, Ainara Soria, Enrique Espinosa Arranz, Javier Martínez, Alfonso Berrocal, José Miguel Jurado García, Isabel Palacio, Ovidio Fernández, Miguel-Ángel Berciano-Guerrero, Ana Arance
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Consejería de Sanidad de la Comunidad de Madrid
Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, observational study involved 135 patients with unre
Autor:
Caroline Robert, Richard F. Kefford, Jean-Jacques Grob, Axel Hauschild, Enrique Espinosa, Salvador Martin Algarra, Dirk Schadendorf, Piotr Rutkowski, Alexander M.M. Eggermont, Helen Gogas, Reinhard Dummer
The molecular classification of melanoma and the advent of new drugs are changing the paradigm of therapy for advanced melanoma. A review of the recent key studies was performed, followed by a discussion in an expert forum. The aim of this review was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a96f3d619d2431095cf9a737795be276
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84921435382
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84921435382
Autor:
José Manuel Aramendía, Jose Manuel Ordoñez, Javier Aristu, Salvador Martin Algarra, Rafael Martínez Monje, Esteban Salgado, Maria Gonzalez Cao, Antonio Brugarolas
Publikováno v:
American Journal of Clinical Oncology. 25:480-484
The purpose of this study was to evaluate the efficacy and tolerance of combined irinotecan and vinorelbine in previously treated patients with stage IIIB and IV non-small-cell lung cancer (NSCLC). Thirty-three patients with NSCLC (7 stage IIIB and 2
Autor:
G. Crespo, Elisabeth Pérez-Ruiz, Maria Gonzalez-Cao, Ana Gimenez Capitan, Maria de los Llanos Gil, Rafael Rosell, Daniela Morales-Espinosa, Delvys Rodriguez-Abreu, Niki Karachaliou, Santiago Viteri Ramirez, Salvador Martin Algarra, Teresa Puertolas, Miguel Angel Molina-Vila, Erika Aldeguer, Ivan Marquez Rodas, R. Blanco, Cristina Teixidó, Ana Drozdowskyj, Maria Angeles Royo
Publikováno v:
Journal of Clinical Oncology. 35:11504-11504
11504 Background: PD-L1 can be induced by oncogenic signals or up-regulated via INFG in a STAT1- and NFκB-dependent manner. STAT3 opposes STAT1-mediated anti-tumor immune responses. I kappa B kinase epsilon (IKBKE) is an interferon signaling inducer
Autor:
Lorenzo Alonso, Enrique Espinosa, Alfonso Berrocal, Ana Arance, Javier Valdivia, Eva Muñoz, Salvador Martin Algarra, Virtudes Soriano, Pilar Lopez Criado, José Antonio López Martín
Publikováno v:
Melanoma Research
Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnai
Autor:
Salvador Martin Algarra, Teresa Puertolas, Maria Gonzalez-Cao, Ainara Soria, Elisabeth Perez Ruiz, Pilar Mut Sanchis, Almudena García Castaño, Carlos Aguado, Delvys Rodriguez, Josep M. Piulats, Maria Angeles Royo, Clara Montagut, Ivan Marquez Rodas, Miguel Angel Berciano Guerrero, Remei Blanco, Guillermo Crespo, Alfonso Berrocal, Jose Luis Manzano, Eva Muñoz-Couselo, Ana Arance
Publikováno v:
Journal of Clinical Oncology. 34:e21029-e21029
e21029Background: The programmed death (PD-1) inhibitor pembrolizumab has recently been approved for treatment of advanced melanoma patients (p), based on a significant improvement in terms of surv...
Autor:
Pablo Cerezuela, Salvador Martin Algarra, Enrique Espinosa, Alfonso Berrocal, Jose I. Mayordomo, Maria Gonzalez Cao, José Antonio López Martín
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 14(5)
After several decades of slow progress in the field of melanoma, significant advances have been reported in recent years. These include a better understanding of the molecular biology of the tumour, a new staging classification system, insights into